Abstract
Research into new antipsychotics is in a fruitful development. The molecular identification of various subtypes of receptors, and also transporters, for dopamine and serotonin has led to promising possibilities for developing new, better, and more side effect-Free antipsychotics. New and selective dopamine antagonists will emerge, with varying therapeutic effects, but with fewer side effects than current neuroleptics. DI antagonists are interesting in this respect, but it may be that combinations of D1, D2, D3 and D4 receptor blockers represent the strongest possibilities (i.e. clozapine). Serotonin agents, given separately or incorporated into a neuroleptic, are another area of considerable potential. The new antipsychotic risperidone, acting through a combination of strong 5HT2/D2 receptor antagonism. may contribute to our understanding of the importance of SHT2 antagonism in antipsychotic drugs. The observation of a beneficial effect of selective serotonin reuptdke inhibitors in subgroups of schizophre...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
